Equity Brief · Healthcare2026-05-20
BAYN.DE·Healthcare

Bayer AG NA

I · AI-analyse

In het kort

Bayer makes prescription medicines for heart disease, women's health, cancer, and blood disorders; sells consumer brands like Midol and Aspirin; and provides seeds, pesticides, and digital farming tools to agriculture customers worldwide [Yahoo Finance]. The Crop Science division is the largest profit contributor, generating nearly half of total revenue [Simply Wall St].

Bayer is a 161-year-old German life sciences giant operating three major divisions: prescription drugs (Pharmaceuticals), over-the-counter health products (Consumer Health), and agricultural seeds and crop chemicals (Crop Science) [Yahoo Finance]. The company currently reports a €2.2 billion net loss on €45.6 billion in revenue, but recent news signals potential recovery through two FDA priority-review drugs in stroke prevention and lung cancer [Yahoo Finance]. Bayer also faces ongoing environmental liabilities, including a recent $133 million settlement for PCB contamination cleanup [Seeking Alpha].

Bayer is currently unprofitable with moderate debt levels, but maintains strong gross margins and positive free cash flow [Yahoo Finance].

In het kort AI analysisBetrouwbaarheid 7/10

Sentinellis-score

4.2/10

Moderate concerns

Marktkapitalisatie

EUR 37.8B

Omzet (12 maanden)

EUR 45.6B

II · Recent nieuws

Wat de koers bewoog

6 stories · ranked by relevance

  • macro2026-05-20

    BAYRY or RHHBY: Which Is the Better Value Stock Right Now?

    Zacks

  • macro2026-05-20

    Should FDA Priority Review for HYRNUO’s First-Line Lung Cancer Use Require Action From Bayer (XTRA:BAYN) Investors?

    Yahoo Finance

  • macro2026-05-19

    Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention

    Yahoo Finance

  • macro2026-05-19

    Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

    Yahoo Finance

  • macro2026-05-19

    FDA Grants Priority Tag to Bayer's Oncology Drug for First-Line NSCLC

    Yahoo Finance

  • macro2026-05-17

    Assessing Bayer (XTRA:BAYN) Valuation After Mixed Share Performance And Profit Recovery Hopes

    Simply Wall St

Premium · gratis met elk account

Bayer reported a €2.2 billion net loss for the most recent fiscal year despite €45.6 billion in revenue, and the company remains unprofitable with a negative net margin of -7.9% [Yahoo Finance]

1 van 5 risico's in dit rapport

Risico's

5

Kansen

5

Waarschuwingssignalen

3

Leiding

10

Nog 22 bevindingen in het volledige rapport — gratis met elk account.

Ontgrendel de volledige analyse van Bayer AG NA

Maak een gratis account voor het volledige AI-rapport met bronvermelding in de tekst.

  • 5 risico's, 5 kansen en 3 waarschuwingssignalen — elk met zijn bron
  • Meer dan 100 financiële cijfers met grafieken en vergelijkingen
  • Volledige nieuwssamenvattingen met bronlinks
  • Directie en beloning
  • PDF-export voor offline
Ontgrendel alle 13 bevindingen3 gratis rapporten · geen creditcard

III · Vergelijkbare bedrijven

Misschien ook interessant

Same sector · Healthcare or comparable health

Op je volglijst zetten?

Read three companies free. Geen kaart.

Krijg 3 gratis rapporten